TY - JOUR
T1 - Human RIPK1 deficiency causes combined immunodeficiency and inflammatory bowel diseases
AU - Li, Yue
AU - Führer, Marita
AU - Bahrami, Ehsan
AU - Socha, Piotr
AU - Klaudel-Dreszler, Maja
AU - Bouzidi, Amira
AU - Liu, Yanshan
AU - Lehle, Anna S.
AU - Magg, Thomas
AU - Hollizeck, Sebastian
AU - Rohlfs, Meino
AU - Conca, Raffaele
AU - Field, Michael
AU - Warner, Neil
AU - Mordechai, Slae
AU - Shteyer, Eyal
AU - Turner, Dan
AU - Boukari, Rachida
AU - Belbouab, Reda
AU - Walz, Christoph
AU - Gaidt, Moritz M.
AU - Hornung, Veit
AU - Baumann, Bernd
AU - Pannicke, Ulrich
AU - Idrissi, Eman Al
AU - Alghamdi, Hamza Ali
AU - Sepulveda, Fernando E.
AU - Gil, Marine
AU - De Saint Basile, Geneviève
AU - Hönig, Manfred
AU - Koletzko, Sibylle
AU - Muise, Aleixo M.
AU - Snapper, Scott B.
AU - Schwarz, Klaus
AU - Klein, Christoph
AU - Kotlarz, Daniel
N1 - Publisher Copyright:
© 2019 National Academy of Sciences. All Rights Reserved.
PY - 2019/1/15
Y1 - 2019/1/15
N2 - Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a critical regulator of cell death and inflammation, but its relevance for human disease pathogenesis remains elusive. Studies of monogenic disorders might provide critical insights into disease mechanisms and therapeutic targeting of RIPK1 for common diseases. Here, we report on eight patients from six unrelated pedigrees with biallelic loss-of-function mutations in RIPK1 presenting with primary immunodeficiency and/ or intestinal inflammation. Mutations in RIPK1 were associated with reduced NF-κB activity, defective differentiation of T and B cells, increased inflammasome activity, and impaired response to TNFR1-mediated cell death in intestinal epithelial cells. The characterization of RIPK1-deficient patients highlights the essential role of RIPK1 in controlling human immune and intestinal homeostasis, and might have critical implications for therapies targeting RIPK1.
AB - Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) is a critical regulator of cell death and inflammation, but its relevance for human disease pathogenesis remains elusive. Studies of monogenic disorders might provide critical insights into disease mechanisms and therapeutic targeting of RIPK1 for common diseases. Here, we report on eight patients from six unrelated pedigrees with biallelic loss-of-function mutations in RIPK1 presenting with primary immunodeficiency and/ or intestinal inflammation. Mutations in RIPK1 were associated with reduced NF-κB activity, defective differentiation of T and B cells, increased inflammasome activity, and impaired response to TNFR1-mediated cell death in intestinal epithelial cells. The characterization of RIPK1-deficient patients highlights the essential role of RIPK1 in controlling human immune and intestinal homeostasis, and might have critical implications for therapies targeting RIPK1.
KW - Inflammatory bowel diseases |
KW - Primary immunodeficiency |
KW - Rare diseases
UR - http://www.scopus.com/inward/record.url?scp=85060065060&partnerID=8YFLogxK
U2 - 10.1073/pnas.1813582116
DO - 10.1073/pnas.1813582116
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 30591564
AN - SCOPUS:85060065060
SN - 0027-8424
VL - 116
SP - 970
EP - 975
JO - Proceedings of the National Academy of Sciences of the United States of America
JF - Proceedings of the National Academy of Sciences of the United States of America
IS - 3
ER -